Back to News
Market Impact: 0.2
Tivic Health Systems, Inc. Announces Positive Safety Results from Entolimod Study
Source: Nasdaq
Healthcare & Biotech
On October 27, 2026, Tivic Health Systems, Inc., filing as Valion Bio, Inc., announced final data from a safety study of its lead biologic candidate, Entolimod. The article text identifies the drug as designed to protect against and mitigate hematopoietic and gastrointestinal acute radiation syndrome, but provides no study results or safety findings.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
VBIO0.70
More News
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Linde delivers a good quarter and puts in a fix for an overhang on the stock
- Aspen Neuroscience prices IPO at $15 per share
- Aspen Neuroscience prices IPO at $15 per share on Nasdaq